Trial reportDermatologic therapy2022
Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily.
Trial report in Dermatologic therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05296837 (ORBS), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ORBS: Ocular Rosacea Biome Study
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Long-Term Safety Profiles of Macrolides and Tetracyclines: A Systematic Review and Meta-Analysis.Journal of clinical pharmacology · 2024Pooled it
- Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily.Dermatologic therapy · 2022Trial
- Exploring New Dimensions in Longitudinal Rosacea Management.Dermatology and therapy · 2026Review
- A Real-World Retrospective Cohort Study Evaluating Clinical Effects and Safety of Radiofrequency Microneedling for the Treatment of Rosacea.Clinical, cosmetic and investigational dermatology · 2026Article
- Inflammatory memory as a potential driver of rosacea pathogenesis: integrating mechanisms of chronic relapse and perspectives on disease modification.Frontiers in immunology · 2026Review
- Rosacea in Older Adults and Pharmacologic Treatments.Drugs & aging · 2024Review
- Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape.Drugs · 2024Review
- Rosacea: Practical Guidance and Challenges for Clinical Management.Clinical, cosmetic and investigational dermatology · 2024Review
- Tetracyclines Revisited: Tetracyclines in the Field of Dermatology.Dermatology (Basel, Switzerland) · 2024Review
- Effective Treatment of Inflammatory Lesions of Rosacea with Subantibiotic Dose Doxycycline Irrespective of Patient Weight or Baseline Lesion Count Severity.The Journal of clinical and aesthetic dermatology · 2022Article
- How to Optimize Rosacea Treatment for Better Patient Outcomes: An Opinion Piece.The Journal of clinical and aesthetic dermatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An important goal of effective rosacea treatment is to maximize the duration of remission. This was a two-part study. Part 1 was a multicenter, open-label, 12-week study in which adults with moderate or severe inflammatory lesions (papules and pustules) of rosacea received subantibiotic dose oral doxycycline 40 mg modified release (SDD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.